Abstract
Background: The use of triptans in the treatment of migraine was a breakthrough. Their selective agonistic action at serotonin (5-hydroxytryptamine) receptors has provided insights into the pathophysiology of migraine and represented a significant advance in migraine pharmacotherapy. Sumatriptan was the first synthesized triptan available for clinical use in the United States. Although it revolutionized the treatment of migraine, it demonstrated some drawbacks, e.g. poor oral bioavailability, erratic absorption, and high rate of headache recurrence. New triptans have been developed namely; almotriptan, zolmitriptan, rizatriptan, eletriptan, frovatriptan and naratriptan, with each one demonstrating specific pharmacokinetic parameters that may be translated into clinical advantage. Although second generation triptans possess better bioavailability compared to sumatriptan, they all still need improvement.
Objective: This review illustrates a survey for the available researches aimed to enhance triptans’ bioavailability and hence effectiveness, either by investigating alternative routes of administration, other than oral route and/or designing appropriate formulations.
Results: Promising results were gained by many researchers after studying different routes for triptans’ administration, e.g. nasal, buccal, sublingual, transdermal and pulmonary using well designed formulations, e.g. nanocarriers, microcarriers, orodispersible tablets or films, in situ gels, microneedles for transdermal application, etc.
Conclusion: Utilizing alternative routes for triptans’ administration in addition to designing appropriate formulations, were successful approaches. However, further investigations should be conducted to establish their bioavailability and in vitro- in vivo correlation studies are also required, to confirm the potential of the designed formulations for use in humans, hence novel efficient triptans’ formulations may appear on the market in the near future.
Keywords: Bioavailability, Formulations, Migraine, Routes of administration, Triptans.
Graphical Abstract
Current Drug Delivery
Title:Formulation Approaches of Triptans for Management of Migraine
Volume: 13 Issue: 6
Author(s): Abeer Ahmed Kassem
Affiliation:
Keywords: Bioavailability, Formulations, Migraine, Routes of administration, Triptans.
Abstract: Background: The use of triptans in the treatment of migraine was a breakthrough. Their selective agonistic action at serotonin (5-hydroxytryptamine) receptors has provided insights into the pathophysiology of migraine and represented a significant advance in migraine pharmacotherapy. Sumatriptan was the first synthesized triptan available for clinical use in the United States. Although it revolutionized the treatment of migraine, it demonstrated some drawbacks, e.g. poor oral bioavailability, erratic absorption, and high rate of headache recurrence. New triptans have been developed namely; almotriptan, zolmitriptan, rizatriptan, eletriptan, frovatriptan and naratriptan, with each one demonstrating specific pharmacokinetic parameters that may be translated into clinical advantage. Although second generation triptans possess better bioavailability compared to sumatriptan, they all still need improvement.
Objective: This review illustrates a survey for the available researches aimed to enhance triptans’ bioavailability and hence effectiveness, either by investigating alternative routes of administration, other than oral route and/or designing appropriate formulations.
Results: Promising results were gained by many researchers after studying different routes for triptans’ administration, e.g. nasal, buccal, sublingual, transdermal and pulmonary using well designed formulations, e.g. nanocarriers, microcarriers, orodispersible tablets or films, in situ gels, microneedles for transdermal application, etc.
Conclusion: Utilizing alternative routes for triptans’ administration in addition to designing appropriate formulations, were successful approaches. However, further investigations should be conducted to establish their bioavailability and in vitro- in vivo correlation studies are also required, to confirm the potential of the designed formulations for use in humans, hence novel efficient triptans’ formulations may appear on the market in the near future.
Export Options
About this article
Cite this article as:
Kassem Ahmed Abeer, Formulation Approaches of Triptans for Management of Migraine, Current Drug Delivery 2016; 13 (6) . https://dx.doi.org/10.2174/1567201813666160425112600
DOI https://dx.doi.org/10.2174/1567201813666160425112600 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Message from the Editor-in-Chief
CNS & Neurological Disorders - Drug Targets Acetylcholinesterase Inhibitors as a Starting Point Towards Improved Alzheimers Disease Therapeutics
Current Pharmaceutical Design Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
Current Stem Cell Research & Therapy Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Oxytocin in Autism Spectrum Disorders
Current Psychopharmacology Implication of Circadian Rhythms and Melatonin in Major Depressive Disorder: The Evidence Base for New Antidepressant Treatment
Current Psychiatry Reviews Editorial [HotTopic: New and Emerging Approaches to Treatment of Schizophrenia (Guest Editors: Gene G. Kinney and P. Jeffrey Conn)]
Current Neuropharmacology Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Racial Differences in Gray Matter Integrity by Diffusion Tensor in Black and White Octogenarians
Current Alzheimer Research Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX
Letters in Drug Design & Discovery Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke
Current Neurovascular Research Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry A Primary Reduced TCA Flux Governs Substrate Oxidation in T2D Skeletal Muscle
Current Diabetes Reviews Electrochemical Biosensor for the Detection of Glycated Albumin
Current Alzheimer Research ERRATUM
Current Neuropharmacology Synthesis, Biological Evaluation and in silico Studies of Novel 5α-aza-Bhomo-3,5-secosteroids as Potential 5-reductase Inhibitors
Letters in Drug Design & Discovery Jun Dimerization Protein 2: A Multifunctional Transcription Factor in Mammalian Cells
Current Genomics